TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16364860

Group type: EXPERIMENTAL
Intervention: Low C2 (<1,000 microg/liter, n = 18)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Intermediate C2 (1,000-1,500 microg/liter, n = 16)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: High C2 (>1,500 microg/liter, n = 14)
Number of subjects: 48
Study: 12215081

Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combined CM and CBT (CBT + CM)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Treatment as usual (MMTP only)
Number of subjects: 120
Study: 10527085

Group type: EXPERIMENTAL
Intervention: Salbutamol (2mg)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo (ascorbic acid, 50mg)
Number of subjects: 3
Study: 7482648

Group type: EXPERIMENTAL
Intervention: BY963 (spherosome suspension containing a phospholipid), administered in three doses (2.5, 5, and 10 mL) at four different injection rates (0.25, 0.5, and 1 mL/s and bolus)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: BY963 (spherosome suspension containing a phospholipid)
Number of subjects: 8
Study: 1932407

Group type: EXPERIMENTAL
Intervention: amitriptyline
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: fluoxetine
Number of subjects: 40

Group type: COMPARATOR
Intervention: control (normal healthy volunteers)
Number of subjects: 40
Study: 6319244

Group type: EXPERIMENTAL
Intervention: Coarse wheat bran
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30276532

Group type: COMPARATOR
Intervention: PH1-T (after combined kidney liver transplantation)
Number of subjects: 115

Group type: COMPARATOR
Intervention: PH1-Cons (under conservative treatment)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Cont-T (patients with a past of renal transplantation)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Cont-H (healthy controls)
Number of subjects: 115
Study: 28661195

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (standard course)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (optimised course)
Number of subjects: 50
Study: 27084025

Group type: EXPERIMENTAL
Intervention: 6‐week behavioral, positive parenting, and peer monitoring skills intervention
Number of subjects: 89

Group type: COMPARATOR
Intervention: General health education comparison condition
Number of subjects: 89
Study: 24976429

Group type: EXPERIMENTAL
Intervention: Aged black garlic (ABG), 6 g/d, twice daily for 12 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo, twice daily for 12 weeks
Number of subjects: 60
Study: 23084274

Group type: EXPERIMENTAL
Intervention: Tulip fibre
Number of subjects: 174

Group type: COMPARATOR
Intervention: Bare fibre
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Tulip fibre and Bare fibre
Number of subjects: 174
Study: 20671623

Group type: EXPERIMENTAL
Intervention: Stronger neo-minophagen C (SNMC)
Number of subjects: 36

Group type: COMPARATOR
Intervention: S-adenosyl-L-methionine (SAM)
Number of subjects: 36
Study: 17950791

Group type: EXPERIMENTAL
Intervention: Heparin plus planned glycoprotein IIb/IIIa inhibitor (GPI)
Number of subjects: 6001

Group type: COMPARATOR
Intervention: Bivalirudin plus provisional GPIs
Number of subjects: 6001

Group type: EXPERIMENTAL
Intervention: Major hemorrhage
Number of subjects: 6001
Study: 16343666

Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy (Aspirin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anticoagulant therapy (Warfarin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 14769724

Group type: EXPERIMENTAL
Intervention: Tidal breathing method
Number of subjects: 12

Group type: COMPARATOR
Intervention: Dosimeter method
Number of subjects: 12
Study: 10714084

Group type: EXPERIMENTAL
Intervention: Asthmatics
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Moderate to severe asthmatics
Number of subjects: 35
Study: 8960591

Group type: EXPERIMENTAL
Intervention: Calcium score of 5 using fast computed tomography
Number of subjects: 100

Group type: COMPARATOR
Intervention: Smooth, luminally normal coronary arteries
Number of subjects: 100
Study: 1389192

Group type: EXPERIMENTAL
Intervention: Lidocaine inhalation 40 mg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Lidocaine inhalation 120 mg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) lidocaine 1 mg/kg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Saline inhalation (placebo)
Number of subjects: 80
Study: 3158325

Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nitrendipine 10 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nitrendipine 20 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31270591

Group type: EXPERIMENTAL
Intervention: CT-based patient-specific instruments (PSI)
Number of subjects: 124

Group type: COMPARATOR
Intervention: MRI-based patient-specific instruments (PSI)
Number of subjects: 124
Study: 30325453

Group type: EXPERIMENTAL
Intervention: PreKT
Number of subjects: 1138

Group type: COMPARATOR
Intervention: DiaKT
Number of subjects: 1138
Study: 28687670

Group type: EXPERIMENTAL
Intervention: Stand-alone PVI
Number of subjects: 118

Group type: COMPARATOR
Intervention: PVI plus Substrate modification
Number of subjects: 118
Study: 25945935

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided pulsed radio frequency treatment
Number of subjects: 20
Study: 24286801

Group type: EXPERIMENTAL
Intervention: Intra-articular injection of cultured MSCs with hyaluronic acid 3 weeks after surgery
Number of subjects: 56

Group type: COMPARATOR
Intervention: Hyaluronic acid
Number of subjects: 56
Study: 21519084

Group type: EXPERIMENTAL
Intervention: Herbert screw fixation
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Matti Russe bone grafting
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Kohlman modification of vascularised muscle pedicle graft procedure
Number of subjects: 33

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 33
Study: 18641189

Group type: EXPERIMENTAL
Intervention: CLA mixture (trans-10, cis-12 conjugated linoleic acid)
Number of subjects: 75

Group type: COMPARATOR
Intervention: CLA milk (cis-9, trans-11 conjugated linoleic acid)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Olive oil
Number of subjects: 75
Study: 17061710

Group type: EXPERIMENTAL
Intervention: Topography-guided customized corneal LASIK (CATz)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Conventional LASIK (NAVEX)
Number of subjects: 23
Study: 14534919

Group type: EXPERIMENTAL
Intervention: Pramipexole (PPX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bromocriptine (BR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10920064

Group type: EXPERIMENTAL
Intervention: IVUS-guided stent deployment
Number of subjects: 525

Group type: COMPARATOR
Intervention: Angiographic guidance alone
Number of subjects: 525
Study: 8848258

Group type: EXPERIMENTAL
Intervention: Repeated tone in a tone sequence
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mismatch negativity
Number of subjects: 0
Study: 1411403

Group type: EXPERIMENTAL
Intervention: Triple therapy (tetracycline, ornidazole, bismuth subcitrate)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Omeprazole/bismuth subcitrate (O/CBS)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 13C‐urea breath test
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: HP serology
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Meal-stimulated gastrin release
Number of subjects: 10
Study: 3931154

Group type: EXPERIMENTAL
Intervention: Scopolamine (centrally active anticholinergic drug) administered in three different intravenous doses
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30723098

Group type: EXPERIMENTAL
Intervention: 8-week group-based healthy eating and physical activity intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study: 29566206

Group type: EXPERIMENTAL
Intervention: Actissist (digital health intervention delivered via smartphone app over 12 weeks)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Actissist
Number of subjects: 36
Study: 27720984

Group type: EXPERIMENTAL
Intervention: IPI (interactive photo interface)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: SBI (sketching-based interface)
Number of subjects: 108

Group type: COMPARATOR
Intervention: TLP (traditional life-size photo)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: IPI
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: SBI
Number of subjects: 108
Study: 24435411

Group type: EXPERIMENTAL
Intervention: Standard Intervention (SI)
Number of subjects: 945

Group type: EXPERIMENTAL
Intervention: Tailored Navigation Intervention (TNI)
Number of subjects: 945

Group type: COMPARATOR
Intervention: Usual Care Control
Number of subjects: 945
Study: 23131879

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 37

Group type: COMPARATOR
Intervention: Ziprasidone
Number of subjects: 37
Study: 19891620

Group type: EXPERIMENTAL
Intervention: Autologous stem cell treatment for cardiac repair
Number of subjects: 0
Study: 17627698

Group type: EXPERIMENTAL
Intervention: Epiphany/Resilon (experimental)
Number of subjects: 60

Group type: COMPARATOR
Intervention: gutta‐percha/AH Plus (control)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Chloroform (used in both groups)
Number of subjects: 60
Study: 13680074

Group type: EXPERIMENTAL
Intervention: Tryptophan depletion
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Current MDMA users
Number of subjects: 96

Group type: COMPARATOR
Intervention: Non-MDMA substance users
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Trait aggression
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Impulsivity
Number of subjects: 96
Study: 11355477

Group type: EXPERIMENTAL
Intervention: Videorentgenocinematographic examinations after partial laryngectomy
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Reconstruction of defects in a part of the base of the tongue with a vascular pedicle flap of the submandibular gland
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (35 subjects)
Number of subjects: 81
Study: 9391668

Group type: EXPERIMENTAL
Intervention: Active treatment (middle ear pressure changes)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 39
Study: 8430715

Group type: EXPERIMENTAL
Intervention: Immunologic therapy with dialyzable leukocyte extract
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combination of immunologic therapy and CBT
Number of subjects: 90

Group type: COMPARATOR
Intervention: Nonspecific treatment regimens
Number of subjects: 90
Study: 3318897

Group type: EXPERIMENTAL
Intervention: Felodipine 2.5 mg twice daily
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 30798674

Group type: EXPERIMENTAL
Intervention: Treatment supporters providing medical and social support to PLWHA
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Open communication and committed emotional support from treatment supporters
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Training and systemic support for treatment supporters
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Lack of HIV-related knowledge among treatment supporters
Number of subjects: 25
Study: 30115112

Group type: EXPERIMENTAL
Intervention: Home-based self-help metacognitive therapy (Home-MCT) plus usual cardiac rehabilitation
Number of subjects: 108

Group type: COMPARATOR
Intervention: Usual cardiac rehabilitation
Number of subjects: 108
Study: 26735552

Group type: EXPERIMENTAL
Intervention: Cold water immersion
Number of subjects: 20

Group type: COMPARATOR
Intervention: Passive recovery
Number of subjects: 20
Study: 24411003

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg plus ezetimibe
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atorvastatin 20 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atorvastatin 40 mg
Number of subjects: 0
Study: 22278986

Group type: EXPERIMENTAL
Intervention: Lack of strong motivation for physical activity
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Lack of strong beliefs related to physical activity
Number of subjects: 176
Study: 20814815

Group type: EXPERIMENTAL
Intervention: Capecitabine plus enzastaurin (1,250 mg/m² twice daily plus 500 mg/day)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Capecitabine plus placebo
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Capecitabine plus enzastaurin
Number of subjects: 85
Study: 17551305

Group type: EXPERIMENTAL
Intervention: Docetaxel plus gemcitabine (docetaxel 75 mg/m2 on day 8 and gemcitabine 1000 mg/m2 on day 1 and day 8 every 3 weeks for 6 cycles)
Number of subjects: 40
Study: 15867552

Group type: EXPERIMENTAL
Intervention: Intralesional corticosteroid injection (CSI)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control group (standardized stretching program only)
Number of subjects: 132
Study: 11935098

Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Muscular endurance training
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Coordination training
Number of subjects: 126

Group type: COMPARATOR
Intervention: Non-training reference group
Number of subjects: 126
Study: 10487482

Group type: EXPERIMENTAL
Intervention: Hypolipidemic diet for 3 months
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Hypolipidemic diet
Number of subjects: 53

Group type: COMPARATOR
Intervention: Matched responders (10)
Number of subjects: 53
Study: 8726539

Group type: EXPERIMENTAL
Intervention: Cabergoline (up to 5 mg daily)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Cabergoline (10 mg daily in open-label phase)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Cabergoline (higher doses)
Number of subjects: 13
Study: 1762811

Group type: EXPERIMENTAL
Intervention: 100 ml of a mannitol solution containing 7.5 mg/kg L‐tryptophan
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 100 ml of a mannitol solution containing 15 mg/kg L‐tryptophan
Number of subjects: 45

Group type: COMPARATOR
Intervention: 100 ml of 5% mannitol solution i.v.
Number of subjects: 45
Study: 6210867

Group type: EXPERIMENTAL
Intervention: Danazol 100 mg/day
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Danazol 200 mg/day
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Danazol 400 mg/day
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Danazol 600 mg/day
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Danazol (various doses)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Danazol (600 mg/day) with amenorrhea
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Post-treatment follow-up
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Post-treatment follow-up in infertile patients
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Comparison of infertile patients who conceived vs. did not conceive
Number of subjects: 27
Study: 31621845

Group type: EXPERIMENTAL
Intervention: Listening to music
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Watching cartoons
Number of subjects: 191

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 191
Study: 28817342

Group type: EXPERIMENTAL
Intervention: Basal insulin peglispro (BIL)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Insulin glargine (GL)
Number of subjects: 68
Study: 25748293

Group type: EXPERIMENTAL
Intervention: Minodronic acid 1 mg (single dose)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Minodronic acid 1 mg (repeated doses for 7 days)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Minodronic acid 4 mg (single dose under fed conditions)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Minodronic acid (various doses 1, 2, and 4 mg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Minodronic acid (general findings)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Minodronic acid (food effect)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Minodronic acid (age effect)
Number of subjects: 48
Study: 25675570

Group type: EXPERIMENTAL
Intervention: Elongated needle therapy at Tiantu (CV 22)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Regular needle therapy at Tiantu (CV 22)
Number of subjects: 71
Study: 20864611

Group type: EXPERIMENTAL
Intervention: LET'S intervention (n=178)
Number of subjects: 352

Group type: COMPARATOR
Intervention: Usual care (n=174)
Number of subjects: 352
Study: 18363059

Group type: EXPERIMENTAL
Intervention: Thoracic epidural analgesia (TEA)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Non-TEA
Number of subjects: 75
Study: 17543140

Group type: EXPERIMENTAL
Intervention: Acetyl L-carnitine (LAC) 500 mg, 2 capsules/day plus 500 mg i.m. injection for 2 weeks, then 3 capsules/day for 8 weeks
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo, 2 capsules/day plus placebo i.m. injection for 2 weeks, then placebo for 8 weeks
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Acetyl L-carnitine (LAC)
Number of subjects: 102
Study: 14749760

Group type: EXPERIMENTAL
Intervention: Mineral water fortified with folic acid (563 microg/day), vitamins B(6) (1 mg/day), B(12) (7.5 microg/day), cholecalciferol (0.6 microg/day), and calcium (563 mg/day)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo mineral water
Number of subjects: 66
Study: 10604327

Group type: EXPERIMENTAL
Intervention: Soluble fiber diet
Number of subjects: 14

Group type: COMPARATOR
Intervention: Insoluble fiber diet
Number of subjects: 14
Study: 9362599

Group type: EXPERIMENTAL
Intervention: Problem-based education program
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study: 1606348

Group type: EXPERIMENTAL
Intervention: 200 mg intravenous ciprofloxacin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 300 mg intravenous ciprofloxacin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 400 mg intravenous ciprofloxacin
Number of subjects: 0
Study: 4003485

Group type: EXPERIMENTAL
Intervention: Hypertonic solution (670 ml Osmol)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Hypotonic solution (224 ml Osmol)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (5 patients)
Number of subjects: 20
Study: 3591898

Group type: EXPERIMENTAL
Intervention: Paraperm O2 lenses
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Boston II lenses
Number of subjects: 6
Study: 28929521

Group type: COMPARATOR
Intervention: Radavirsen 0.5 mg kg-1 to 8 mg kg-1 (single ascending doses)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Radavirsen 8 mg kg-1 (multiple doses)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo (single ascending doses)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo (multiple doses)
Number of subjects: 56
Study: 28069045

Group type: EXPERIMENTAL
Intervention: Standard feedback strategy
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Assisted feedback strategy
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Goal-directed feedback strategy
Number of subjects: 203
Study: 26024304

Group type: EXPERIMENTAL
Intervention: rosiglitazone
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: repaglinide
Number of subjects: 209
Study: 23074151

Group type: EXPERIMENTAL
Intervention: Thrombus aspiration (TA) during pPCI
Number of subjects: 3235

Group type: COMPARATOR
Intervention: No thrombus aspiration (TA) during pPCI
Number of subjects: 3235
Study: 21080920

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Corticosteroid
Number of subjects: 315

Group type: COMPARATOR
Intervention: 0.125% Bupivacaine
Number of subjects: 315
Study: 18226760

Group type: EXPERIMENTAL
Intervention: computer-based outreach intervention
Number of subjects: 158
Study: 16446748

Group type: EXPERIMENTAL
Intervention: Tissue Monitoring System (TMS) - participants weighed themselves daily and received feedback on weight changes via email.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group - participants were weighed at the beginning and the end of the semester without daily monitoring.
Number of subjects: 0
Study: 12972470

Group type: EXPERIMENTAL
Intervention: Harris Hip Score
Number of subjects: 75

Group type: COMPARATOR
Intervention: Walking speed
Number of subjects: 75

Group type: COMPARATOR
Intervention: Pain during walking
Number of subjects: 75

Group type: COMPARATOR
Intervention: SF-36 bodily pain
Number of subjects: 75

Group type: COMPARATOR
Intervention: SF-36 physical functioning
Number of subjects: 75
Study: 11005266

Group type: EXPERIMENTAL
Intervention: Cabergoline (CAB) 0.5 mg twice weekly
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Quinagolide (QUI) 75 microg once daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cabergoline (CAB)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Quinagolide (QUI)
Number of subjects: 20
Study: 9172129

Group type: EXPERIMENTAL
Intervention: Intermittent auditory input in children
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Frequent auditory input in children
Number of subjects: 0

Group type: COMPARATOR
Intervention: Auditory N100 responses in adults
Number of subjects: 0
Study: 1287833

Group type: EXPERIMENTAL
Intervention: Procainamide (25 mg/min, max dose 15 mg/kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Digoxin (0.75-1.0 mg intravenously according to renal function and body weight)
Number of subjects: 30
Study: 3920066

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (SCG) with lactose powder
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (SCG) in micropellets without lactose
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (SCG) solution
Number of subjects: 15
Study: 31757216

Group type: EXPERIMENTAL
Intervention: Fine filter cohort (0.2/1.2 μm filters, n=1506)
Number of subjects: 3012

Group type: COMPARATOR
Intervention: Control filter cohort (5.0 μm filters, n=1506)
Number of subjects: 3012